Cargando…

Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects

In recent years, antibody-based cancer therapy has emerged as one of the efficient therapeutic strategies, such as immune checkpoint inhibitors (ICIs), angiogenesis inhibitors, antibody-drug conjugates (ADCs), multi-specific antibodies, and chimeric antigen receptor T (CAR-T) cells, among others. To...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zhoujiang, Kankala, Ranjith Kumar, Yang, Zhiyong, Li, Wei, Xie, Songzhi, Li, Hanmei, Chen, Ai-Zheng, Zou, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131265/
https://www.ncbi.nlm.nih.gov/pubmed/35664074
http://dx.doi.org/10.7150/thno.72594
_version_ 1784713149257089024
author Chen, Zhoujiang
Kankala, Ranjith Kumar
Yang, Zhiyong
Li, Wei
Xie, Songzhi
Li, Hanmei
Chen, Ai-Zheng
Zou, Liang
author_facet Chen, Zhoujiang
Kankala, Ranjith Kumar
Yang, Zhiyong
Li, Wei
Xie, Songzhi
Li, Hanmei
Chen, Ai-Zheng
Zou, Liang
author_sort Chen, Zhoujiang
collection PubMed
description In recent years, antibody-based cancer therapy has emerged as one of the efficient therapeutic strategies, such as immune checkpoint inhibitors (ICIs), angiogenesis inhibitors, antibody-drug conjugates (ADCs), multi-specific antibodies, and chimeric antigen receptor T (CAR-T) cells, among others. To date, various drug delivery platforms have been developed to improve the bioavailability, delivery convenience, and reduced toxicity towards increased therapeutic efficacy of antibodies. Herein, we emphasize the clinical manifestations of various antibody-based tumor therapies, highlighting their mechanisms and applications for cancer therapy. Further, based on the problems to be solved in the current clinical application of antibodies, and combined with the advanced drug delivery technologies, we discuss the roles of antibody-based drug delivery systems (DDSs) in cancer therapy, such as enhanced patient compliance and regulating the tumor microenvironment for combined therapy. By expounding the importance of DDSs and discussing the challenges and prospects of their implementation, we suggest that pharmaceutical enterprises and scientists develop appropriate antibody-based delivery platforms.
format Online
Article
Text
id pubmed-9131265
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-91312652022-06-04 Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects Chen, Zhoujiang Kankala, Ranjith Kumar Yang, Zhiyong Li, Wei Xie, Songzhi Li, Hanmei Chen, Ai-Zheng Zou, Liang Theranostics Review In recent years, antibody-based cancer therapy has emerged as one of the efficient therapeutic strategies, such as immune checkpoint inhibitors (ICIs), angiogenesis inhibitors, antibody-drug conjugates (ADCs), multi-specific antibodies, and chimeric antigen receptor T (CAR-T) cells, among others. To date, various drug delivery platforms have been developed to improve the bioavailability, delivery convenience, and reduced toxicity towards increased therapeutic efficacy of antibodies. Herein, we emphasize the clinical manifestations of various antibody-based tumor therapies, highlighting their mechanisms and applications for cancer therapy. Further, based on the problems to be solved in the current clinical application of antibodies, and combined with the advanced drug delivery technologies, we discuss the roles of antibody-based drug delivery systems (DDSs) in cancer therapy, such as enhanced patient compliance and regulating the tumor microenvironment for combined therapy. By expounding the importance of DDSs and discussing the challenges and prospects of their implementation, we suggest that pharmaceutical enterprises and scientists develop appropriate antibody-based delivery platforms. Ivyspring International Publisher 2022-05-01 /pmc/articles/PMC9131265/ /pubmed/35664074 http://dx.doi.org/10.7150/thno.72594 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Review
Chen, Zhoujiang
Kankala, Ranjith Kumar
Yang, Zhiyong
Li, Wei
Xie, Songzhi
Li, Hanmei
Chen, Ai-Zheng
Zou, Liang
Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects
title Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects
title_full Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects
title_fullStr Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects
title_full_unstemmed Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects
title_short Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects
title_sort antibody-based drug delivery systems for cancer therapy: mechanisms, challenges, and prospects
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131265/
https://www.ncbi.nlm.nih.gov/pubmed/35664074
http://dx.doi.org/10.7150/thno.72594
work_keys_str_mv AT chenzhoujiang antibodybaseddrugdeliverysystemsforcancertherapymechanismschallengesandprospects
AT kankalaranjithkumar antibodybaseddrugdeliverysystemsforcancertherapymechanismschallengesandprospects
AT yangzhiyong antibodybaseddrugdeliverysystemsforcancertherapymechanismschallengesandprospects
AT liwei antibodybaseddrugdeliverysystemsforcancertherapymechanismschallengesandprospects
AT xiesongzhi antibodybaseddrugdeliverysystemsforcancertherapymechanismschallengesandprospects
AT lihanmei antibodybaseddrugdeliverysystemsforcancertherapymechanismschallengesandprospects
AT chenaizheng antibodybaseddrugdeliverysystemsforcancertherapymechanismschallengesandprospects
AT zouliang antibodybaseddrugdeliverysystemsforcancertherapymechanismschallengesandprospects